Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Sebastián García-Sánchez, Roberto Collado-Borrell, Eva González-Haba, José Luis Revuelta-Herrero, Vicente Escudero-Vilaplana, María Belén Marzal-Alfaro, María Norberta Sánchez-Fresneda, Ana Mur-Mur, Ana Herranz, Miguel Martín, María Sanjurjo
Background: Oncology clinical trials can lead to relevant financial savings in drug acquisition for healthcare providers. Considerable methodological heterogeneity is observed among previous studies estimating these savings. Methods: We developed a methodology to estimate the economic benefit obtained from the enrollment of patients into clinical trials through the analysis of drug cost avoidance. We designed a decision algorithm to determine if a clinical trial is associated with drug cost avoidance...
2022: Frontiers in Oncology
#22
REVIEW
David Morland, Elizabeth Katherine Anna Triumbari, Luca Boldrini, Roberto Gatta, Daniele Pizzuto, Salvatore Annunziata
The objective of this review was to summarize published radiomics studies dealing with infradiaphragmatic cancers, blood malignancies, melanoma, and musculoskeletal cancers, and assess their quality. PubMed database was searched from January 1990 to February 2022 for articles performing radiomics on PET imaging of at least 1 specified tumor type. Exclusion criteria includd: non-oncological studies; supradiaphragmatic tumors; reviews, comments, cases reports; phantom or animal studies; technical articles without a clinically oriented question; studies including <30 patients in the training cohort...
May 27, 2022: Diagnostics
#23
JOURNAL ARTICLE
Lorenzo Gasperoni, Alessandro Cafaro, Eleonora Ferretti, Valentina Di Iorio, Oriana Nanni, Carla Masini
OBJECTIVE: Clinical trials offer new and potentially more effective therapeutic options for cancer patients and a potential cost-saving opportunity, especially considering that trial drugs are provided free-of-charge. The aim of this study was to analyse drug-related cost savings in clinical trials in a cancer institute over a 3 year period. The cost savings relate to the pharmaceutical expenditure of our centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"...
May 16, 2022: European Journal of Hospital Pharmacy. Science and Practice
#24
JOURNAL ARTICLE
Anna Cho, Kira Medvedeva, Beate Kranawetter, Helena Untersteiner, Dorian Hirschmann, Olga Lepilina, Anatoly Baulin, Martin Buschmann, Adolf Ertl, Wolfgang Marik, Christian Dorfer, Karl Rössler, Brigitte Gatterbauer, Sergey Ilyalov, Josa M Frischer
OBJECTIVE: The authors sought to evaluate clinical outcome in patients with large, high-risk brain metastases (BMs) treated with different dose strategies by use of two-fraction dose-staged Gamma Knife radiosurgery (GKRS). METHODS: A retrospective analysis was performed with data from 142 patients from two centers who had been treated with two-fraction dose-staged GKRS between June 2015 and January 2020. Depending on the changes in marginal dose between the first (GKRS1) and second (GKRS2) GKRS treatments, the study population was divided into three treatment groups: dose escalation, dose maintenance, and dose de-escalation...
April 15, 2022: Journal of Neurosurgery
#25
JOURNAL ARTICLE
Gaëlle S Nguenang, Armelle T Mbaveng, Idrios N Bonsou, Godloves F Chi, Victor Kuete
Raphia vinifera is widely used to treat several diseases including digestive disorders, dysentery, and genitourinary infections. In this study, the mineral contents, the cytotoxicity, and the toxicological effect of the crude CHCl3 /MeOH extract (RVM) from the mesocarp of Raphia vinifera were evaluated. The mineral contents were evaluated using the method described by the Association of Official Analytical Chemists (AOAC). The cytotoxicity of both extract and chemical compounds from the plants was determined by a resazurin reduction assay (RRA)...
2022: Evidence-based Complementary and Alternative Medicine: ECAM
#26
JOURNAL ARTICLE
H K Björnsson, A Sverrisdottir, E S Björnsson
BACKGROUND: There is limited information on the frequency of idiosyncratic drug-liver injury (DILI) among cancer patients. The aim of the study was to evaluate the frequency of DILI due to cancer treatment in a population-based setting. MATERIAL AND METHODS: All patients diagnosed with genitourinary cancer, breast cancer or metastatic malignant melanoma in 2007-2018 were matched with a database containing laboratory results for all major hospitals in Iceland. Medical chart review was performed for cases with ALT/AST ≥5× upper limit of normal (ULN), ALP ≥2× ULN or bilirubin ≥2× ULN...
July 2022: Scandinavian Journal of Gastroenterology
#27
JOURNAL ARTICLE
J-F Huang, Q-C Tan, H Bai, J Wang, M Bergman, Z Wu
BACKGROUND: Bone mineral deficits are one of the most common complications in cancer survivors. However, there are no studies evaluating bone mineral density (BMD) and the prevalence of osteopenia and osteoporosis among patients with different types of cancers. AIM: The objective was to assess BMD and evaluate the prevalence of osteopenia and osteoporosis among US adults with cancer. DESIGN: A cross-section propensity score matching study...
January 29, 2022: QJM: Monthly Journal of the Association of Physicians
#28
JOURNAL ARTICLE
Zsofia D Drobni, Olivier Michielin, Thiago Quinaglia, Daniel A Zlotoff, Leyre Zubiri, Hannah K Gilman, Sama Supraja, Bela Merkely, Veronika Muller, Ryan J Sullivan, Kerry L Reynolds, Michael J Pittet, Rakesh K Jain, Tomas G Neilan
BACKGROUND: Preclinical studies indicate that the concurrent use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) may improve outcomes in broad groups of patients with cancer. There are limited data on the association between the use of RAAS inhibitors and outcomes among patients treated with immune checkpoint inhibitors (ICIs). METHODS: We performed a retrospective study of all patients treated with an ICI in a single academic network. Of 10,903 patients, 5910 were on any anti-hypertensive medication...
January 19, 2022: European Journal of Cancer
#29
REVIEW
Davide Bimbatti, Marco Maruzzo, Francesco Pierantoni, Alberto Diminutto, Michele Dionese, Filippo M Deppieri, Eleonora Lai, Vittorina Zagonel, Umberto Basso
Immune checkpoint inhibitors (ICIs) have led to a significant change in the treatment of urological tumors where several agents are currently approved. Yet, most patients discontinue treatment due to disease progression or after the onset of severe immune-related adverse events (IRAEs). Following promising results in melanoma patients, retreatment with an ICI is receiving increasing attention as an attractive option for selected patients. We performed a literature review focusing on the feasibility, safety, timing and activity of ICI rechallenge in genitourinary cancers where very little information is available...
February 2022: Critical Reviews in Oncology/hematology
#30
JOURNAL ARTICLE
Joanna Tieu, Susan Lester, Warren Raymond, Helen Keen, Catherine L Hill, Johannes Nossent
OBJECTIVE: The study objective was to compare incident cancer rates among patients with anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) and polyarteritis nodosa (PAN) in Western Australia (WA) with the general population and perform time-varying analyses to identify periods with greatest excess cancers. METHODS: Administrative health data from patients hospitalized with incident AAV/PAN from 1980 to 2014 were linked to the WA cancer registry, which holds compulsorily reported cancer data (excluding skin squamous cell and basal cell carcinomas)...
March 2022: ACR open rheumatology
#31
JOURNAL ARTICLE
Justine Abella Ross, Kellie Komoda, Sumanta Pal, Jana Dickter, Ravi Salgia, Sanjeet Dadwal
BACKGROUND: Immune checkpoint inhibitors (ICIs) are targeted cancer therapies regarded to have less toxicity than chemotherapy. Immune-related adverse events (irAEs) of ICIs are well described in the literature but limited data exist on their infectious complications. The objective is to describe the spectrum and risk factors for developing serious infections in patients receiving ICIs. METHODS: Retrospective review of patients with melanoma, renal cell carcinoma, or nonsmall-cell lung cancer on nivolumab, pembrolizumab, and/or ipilimumab from January 1, 2017 to November 30, 2017...
January 2022: Cancer Medicine
#32
MULTICENTER STUDY
Caroline A Nebhan, Alessio Cortellini, Weijie Ma, Teja Ganta, Haocan Song, Fei Ye, Rebecca Irlmeier, Neha Debnath, Anwaar Saeed, Maluki Radford, Asrar Alahmadi, Akiva Diamond, Christopher Hoimes, Nikhil Ramaiya, Carolyn J Presley, Dwight H Owen, Sarah Abou Alaiwi, Amin Nassar, Biagio Ricciuti, Giuseppe Lamberti, Melissa Bersanelli, Chiara Casartelli, Sebastiano Buti, Paolo Marchetti, Raffaele Giusti, Marco Filetti, Vito Vanella, Domenico Mallardo, Shravanti Macherla, Tamara A Sussman, Andrea Botticelli, Domenico Galetta, Annamaria Catino, Pamela Pizzutilo, Carlo Genova, Maria Giovanna Dal Bello, Foteini Kalofonou, Ella Daniels, Paolo A Ascierto, David J Pinato, Toni K Choueiri, Douglas B Johnson, Thomas U Marron, Yinghong Wang, Abdul Rafeh Naqash
IMPORTANCE: Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population. OBJECTIVE: To provide insight into the clinical outcomes and safety of ICIs among geriatric patients (aged ≥80 years) with cancer...
December 1, 2021: JAMA Oncology
#33
JOURNAL ARTICLE
Omar Abdel-Rahman
Objective: To analyze tumor- and treatment-related factors that might impact the development of certain adverse events (AEs) of potential immune etiology among patients receiving PD-L1 inhibitors. Methods: The FDA Adverse Event Reporting System (FAERS) was accessed, and AE reports related to the use of PD-L1 inhibitors were reviewed. Associations between treatment, tumor type and occurrence of AEs of special interest were analyzed through multivariable logistic regression analysis. Results: A total of 80,304 AE reports were included in the current analysis...
December 2021: Immunotherapy
#34
JOURNAL ARTICLE
Jennifer R Bail, Sumanth V Bail, Jessica Cagle, Koriann Tiesi, Jayla Caffey, Marie Bakitas, Wendy Demark-Wahnefried
BACKGROUND: Approximately 5 million Americans are living with metastatic cancer. Metastatic cancer survivors (MCS) are at risk for poor health behaviors, which may negatively influence well-being. METHODS: Using a modified Dillman protocol, 542 MCS were mailed a survey querying physical and mental health (PROMIS® measures), health behaviors, and supportive care interest. Returned surveys were double-key entered into REDCap®. Data were analyzed using SPSS. RESULTS: Two hundred seventy-seven surveys were returned (51% response)...
February 2022: Supportive Care in Cancer
#35
JOURNAL ARTICLE
Hana Kim, Soomin Ahn, Hongsik Kim, Jung Yong Hong, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Kyoung-Mee Kim, Seung Tae Kim
PURPOSE: Homologous recombination deficiency (HRD) is related to tumorigenesis. Currently, the possibility of HRD as a prognostic biomarker to immune checkpoint inhibitors is unknown. We aimed to investigate whether HRD has potential as a biomarker for immunotherapy. METHODS: The status of homologous recombination deficiency (HRD) was assessed with the next-generation sequencing (NGS) TruSight™ Oncology 500 assay in 501 patients with advanced solid tumor including gastrointestinal (GI), genitourinary (GU), or rare cancer...
September 12, 2021: Journal of Cancer Research and Clinical Oncology
#36
JOURNAL ARTICLE
Davide Mauri, Spyridon Tsiouris, Stefania Gkoura, Ioanna Gazouli, Panagiotis Ntellas, Annalea Amylidis, Lefteris Kampletsas, Andreas Fotopoulos
Immuno-oncology (IO) with immune checkpoint inhibitors (ICIs) is the new landmark in cancer treatment. However, due to its economical-related burden and the possibility of tumor pseudoprogression with late response patterns, it is imperative to find new ways for early discrimination of patients with IO-sensitive versus IO-resistant disease. ICI-mediated antitumor responses depend on tumor immune infiltration by T-cells capable of recognizing and killing tumor cells. Nevertheless, patients may experience different responses to immunotherapy according to their tumor microenvironment and inflammatory infiltration...
August 8, 2021: Cancer Treatment and Research Communications
#37
REVIEW
Yong Qi Leong, Shaun Wen Huey Lee, Khuen Yen Ng
BACKGROUND AND PURPOSE: Increasing evidence suggests significant associations between Parkinson disease (PD) and cancer risks. We conducted an updated review of studies that examined the risks of various cancer among PD patients and how this differed when cancer preceded PD diagnosis or PD diagnosis preceded cancer. METHODS: Four databases were searched for studies that examined the association between PD and incidence of cancer from database inception to 4 June 2021...
December 2021: European Journal of Neurology
#38
JOURNAL ARTICLE
Amy Cunningham-Bussel, Jiaqi Wang, Lauren C Prisco, Lily W Martin, Kathleen M M Vanni, Alessandra Zaccardelli, Mazen Nasrallah, Lydia Gedmintas, Lindsey A MacFarlane, Nancy A Shadick, Mark M Awad, Osama Rahma, Nicole R LeBoeuf, Ellen M Gravallese, Jeffrey A Sparks
OBJECTIVE: To identify predictors of rheumatic immune-related adverse events (irAEs) following immune checkpoint inhibitor (ICI) treatment for cancer. METHODS: We performed a case-control study to predict the occurrence of rheumatic irAEs in cancer patients who initiated ICI treatment at Mass General Brigham and the Dana-Farber Cancer Institute between 2011 and 2020. We screened for the presence of rheumatic irAEs by reviewing the medical records of patients evaluated by rheumatologists or those prescribed nonglucocorticoid immunomodulatory drugs after the time of ICI initiation (baseline)...
August 16, 2021: Arthritis & Rheumatology
#39
JOURNAL ARTICLE
Anna Cho, Helena Untersteiner, Fabian Fitschek, Farjad Khalaveh, Philip Pruckner, Noemi Pavo, Karl Rössler, Christian Dorfer, Brigitte Gatterbauer, Christoph Höller, Manuela Schmidinger, Josa M Frischer
PURPOSE: To investigate the clinical value of the inflammation based prognostic scores for patients with radiosurgically treated brain metastases (BM) originating from non-pulmonary primary tumor (PT). METHODS: A retrospective analysis of 340 BM patients of different PT origin (melanoma, breast, gastrointestinal, or genitourinary cancer) was performed. Pre-radiosurgical laboratory prognostic scores, such as the Neutrophil-to-Lymphocyte Ratio (NLR), the Platelet-to-Lymphocyte Ratio (PLR), Lymphocyte-to-Monocyte Ratio (LMR), and the modified Glasgow Prognostic Score (mGPS), were investigated within 14 days before the first Gamma Knife radiosurgical treatment (GKRS1)...
June 20, 2021: Journal of Neuro-oncology
#40
JOURNAL ARTICLE
Blair Stocks, Hunter Fuentes, Zachary McDowell, Michael Brooks, Jeffrey A Jones
Primary scrotal melanoma represents the rarest genitourinary malignancy. We describe the 25th reported case. The 79-year-old patient presented with a rapidly enlarging right cutaneous scrotal mass which after local excision demonstrated pT4b nodular malignant melanoma (BRAF V600E mutation positive). The patient underwent wide local excision of his hemiscrotum and inguinal lymph node dissection demonstrating nodes positive for melanoma (pN2b). Postoperatively, the patient developed a left sided malignant pleural effusion (M1b)...
April 2021: Canadian Journal of Urology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
